Quality of life in patients with prostatic carcinoma: A review and results of a study in N+ disease. Prostate-specific antigen as predictor of quality of life

Urological Research

Volumn 25, Issue SUPPL. 2, 1997, Pages

  Van Andel, G ^a   Kurth, K H ^a   De Haes, J C J M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW;

EID: 0030923928     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf00941993     Document Type: Review

References (36)

1. Aaronson NK (1991) Methodologic issues in assessing the quality of life of cancer patients. Cancer 67(Suppl):844
2. Aaronson NK, Ahmedzai S, Bergman, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Haes de JCJM, Kaasa S, Klee M, Osaba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F for the European Organization for Research and Treatment of Cancer Study Group on Quality of Life (1993) The European Organization for research and treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Nat Cancer Institute 85:365
3. Barry MJ, Fowler JR, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett ATK and the Measurement Committee of the American Urological Association (1992) The American Urological Association Symptom Index for Benign Prostatic Hyperplasia. J Urol 148:1549
4. Beitz J, Gnecco C, Justice R (1996) Quality-of-life end points in cancer clinical trials: The U.S. Food and Drug Administration Perspective. J Natl Cancer Inst Monogr 20:7
5. Bostwick DG (1995) Prostate-specific antigen and pathology of the prostate. Eur Urol 27(Suppl 2):5
6. Braslis KG, Santa-Cruz C, Brickman AL, Soloway MS (1995) Quality of life 12 months after radical prostatectomy. Br J Urol 75:48
7. Brawer MK (1994) Prostate-specific antigen: critical issues. Urology 44(6S):9
8. Calais da Silva F (1993) Quality of life in prostatic carcinoma. Eur Urol 24(Suppl 2):113
9. Cassileth BR, Soloway MS, Vogelzang NJ, Chou JM, Schellhammer PD, Seidmon EJ, Kennealy GT and members of the Zoladex Prostate Cancer Study Group (1992) Quality of life and psychosocial status in stage D prostate cancer. Qual Life Res 1.323
10. Cella DF, Tulsky DS (1993) Quality of life in cancer: definition, purpose, and method of measurement. Cancer Invest 11:327
11. Cresswell SM, English PJ, Hall RR, Roberts JT, Marsh MM (1995) Pain relief and qualityof life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Br J Urol 76:360
12. De Haes JC (1988) Quality of life: conceptual and theoretical considerations In: Watson M, Greer S, Thomas C (eds) Psychosocial oncology. Oxford University Press, Oxford, p 61
13. Derogatis LR, Kourlesis SM (1981) An approach to evaluation of sexual problems in the cancer patients. CA Cancer J Clin 31.46
14. Donovan K, Sanson-Fisher RW, Redman S (1989) Measuring quality of life in cancer patients. J Clin Oncol 7:959
15. Fosså SD (1994) Quality of life after palliative radiotherapy in patients with hormone-resistant prostate cancer: single institution experience. Br J Urol 74:345
16. Fosså SD, Aaronson NK, Newling D, Van Cangh PJ, Denis L, Kurth KH, de Pauw M and members of the EORTC Genito-Urinary Group (1990) Quality of life and treatment of hormone resistant metastatic prostate cancer. Eur J Cancer 26:1133
17. Fowler FJ Jr, Barry MJ, Lu-Yoa G, Wasson J, Roman A, Wennberg J (1995) Effect of radical prostatectomy for prostate cancer on patient quality of life: results from a medicare survey. Urology 45(6):1007
18. Frohmüller HGW, Theiss M, Manseck A, Wirth MP (1995) Survival and quality of life of patients with stage D1 (T1-3 pN1-2 M0) prostate cancer. Eur Urol 27:202
19. Helgason AR, Fredrikson M, Adolfsson J, Steineck G (1995) Decreased sexual capacity after external radiation therapy for prostate cancer impairs quality of life. Int J Radiat Oncol Biol Phys 32:33
20. Herr HW, Kornblith AB, Ofman U (1993) A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer Suppl 71:1143
21. Kiebert GM, Kaasa S (1996) Quality of life in clinical cancer trials: experience and perspective of the european organization for research and treatment of cancer. J Natl Cancer Inst Monogr 20:91
22. Kleer E, Oesterling JE (1993) PSA and staging of localized prostate cancer. Urol Clin North Am 20:695
23. Kornblith AB, Herr HW, Ofman U (1994) Quality of life of patients with prostate cancer and their spouses. Cancer 73:2791
24. Kramalowsky EV (1988) The value of testosterone deprivation in stage D1 adenocarcinoma of the prostate. J Urol 139:1242
25. Lim AJ, Brandon AH, Fiedler J, Brickman AL, Boyer CI, Raub WA, Soloway MS (1995) Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. J Urol 154:1420
26. Litwin MS, Hays RD, Fink A, Ganz PA, Leak B, Leach GE, Brook RH (1995) Quality of life outcomes in men treated for localized prostate cancer. JAMA 273:129
27. Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B, Coppin C, Neville A, Venner P, Wilson J (1994) Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncology 12:689
28. Pedersen KV, Carlsson P, Rahmquist M, Varenhorst E (1993) Quality of life after radical retropubic prostatectomy for carcinoma of the prostate. Eur Urol 24:7
29. Selby PJ, Chapman JAW, Etazadi-Amoli J (1984) The development of a method for assessing quality of life cancer patients. Br J Cancer 50:13
30. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W (1989) Treatment of metastatic prostate cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590
31. Tyrell CJ (1994) Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. Eur Urol 26(Suppl 1):15
32. Varricchio CG, McCabe MS, Trimble E, Korn EL (1996) Introduction. J Natl Cancer Inst Monogr 20:vii-viii
33. Van Aubel OGJM, Hoekstra WJ, Schröder FH (1985) Early orchiectomy for patients with stage D1 prostatic carcinoma. J Urol 134:292
34. Van de Ouden D, Tribukait B, Blom JHM, Fossa SD, Kurth KH, Ten Kate FJW, Heiden TH, Wang H, Schröder FH, and members of the EORTC GU group (1993) Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. J Urol 150:400
35. Walsh PC, Partin AW, Epstein JI (1994) Cancer control and quality of life following anatomical radical retropubic prostatectomy. results at 10 years. J Urol 152:1831
36. Watkins-Bruner D, Scott C, Lawton C, DelRowe J, Rotman M, Buswell L, Beard C, Cella D (1995) RTOG's first quality of life study- RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 33:901